Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Boston Scientific Corporation (BSX : NYSE)
 
 • Company Description   
Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

Number of Employees: 41,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $39.22 Daily Weekly Monthly
20 Day Moving Average: 10,269,343 shares
Shares Outstanding: 1,429.57 (millions)
Market Capitalization: $56,067.78 (millions)
Beta: 0.81
52 Week High: $47.50
52 Week Low: $37.96
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.31% -4.62%
12 Week -10.76% -1.90%
Year To Date -7.67% 13.59%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
300 BOSTON SCIENTIFIC WAY
-
MARLBOROUGH,MA 01752
USA
ph: 508-683-4000
fax: 508-683-5675
bsxinvestorrelations@bsci.com http://www.bostonscientific.com
 
 • General Corporate Information   
Officers
Michael F. Mahoney - Chief Executive Officer;Chairman of the Board;Pres
Daniel J. Brennan - Executive Vice President and Chief Financial Offic
Jonathan R. Monson - Vice President; Global Controller and Chief Accoun
Nelda J. Connors - Director
Charles J. Dockendorff - Director

Peer Information
Boston Scientific Corporation (BJCT)
Boston Scientific Corporation (CADMQ)
Boston Scientific Corporation (APNO)
Boston Scientific Corporation (UPDC)
Boston Scientific Corporation (IMTIQ)
Boston Scientific Corporation (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 101137107
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/26/22
Share - Related Items
Shares Outstanding: 1,429.57
Most Recent Split Date: 11.00 (2.00:1)
Beta: 0.81
Market Capitalization: $56,067.78 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.42 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.76 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 9.87% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/26/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 22.27
Trailing 12 Months: 23.77
PEG Ratio: 2.26
Price Ratios
Price/Book: 3.35
Price/Cash Flow: 14.50
Price / Sales: 4.61
EPS Growth
vs. Year Ago Period: 5.41%
vs. Previous Quarter: -13.33%
Sales Growth
vs. Year Ago Period: 9.96%
vs. Previous Quarter: -3.23%
ROE
03/31/22 - 14.51
12/31/21 - 14.43
09/30/21 - 12.73
ROA
03/31/22 - 7.48
12/31/21 - 7.40
09/30/21 - 6.48
Current Ratio
03/31/22 - 1.18
12/31/21 - 1.48
09/30/21 - 1.55
Quick Ratio
03/31/22 - -
12/31/21 - 1.10
09/30/21 - 1.15
Operating Margin
03/31/22 - 19.62
12/31/21 - 19.64
09/30/21 - 17.60
Net Margin
03/31/22 - 6.65
12/31/21 - 8.63
09/30/21 - 9.45
Pre-Tax Margin
03/31/22 - 7.46
12/31/21 - 9.05
09/30/21 - 11.02
Book Value
03/31/22 - 11.71
12/31/21 - 11.66
09/30/21 - 11.55
Inventory Turnover
03/31/22 - 2.37
12/31/21 - 2.45
09/30/21 - 2.58
Debt-to-Equity
03/31/22 - 0.54
12/31/21 - 0.53
09/30/21 - 0.54
Debt-to-Capital
03/31/22 - 35.14
12/31/21 - 34.63
09/30/21 - 34.90
 

Powered by Zacks Investment Research ©